Package Leaflet: Information for the User
Ezetimibe/Atorvastatin Olpha 10 mg/10 mg film-coated tablets EFG
Ezetimibe/Atorvastatin Olpha 10 mg/20 mg film-coated tablets EFG
Ezetimibe/Atorvastatin Olpha 10 mg/40 mg film-coated tablets EFG
Ezetimibe/Atorvastatin Olpha 10 mg/80 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Ezetimibe/Atorvastatin Olpha is a medicine that lowers high cholesterol levels. Ezetimibe/Atorvastatin Olpha contains ezetimibe and atorvastatin.
Ezetimibe/atorvastatin is used in adults to lower the levels of total cholesterol, "bad" cholesterol (LDL cholesterol) and substances called triglycerides in the blood. It also raises the levels of "good" cholesterol (HDL cholesterol).
Ezetimibe/atorvastatin works by reducing cholesterol in two ways. It reduces the amount of cholesterol absorbed in the gut and also the amount of cholesterol made by the body.
Cholesterol is one of the fatty substances that can be found in the blood. Your total cholesterol is made up mainly of LDL and HDL cholesterol.
LDL cholesterol is often called "bad" cholesterol because it can build up in the walls of your arteries, forming plaques. Over time, this can lead to a narrowing of the arteries, which can reduce or block blood flow to important organs such as the heart and brain. This blocking of blood flow can cause a heart attack or a stroke.
HDL cholesterol is often called "good" cholesterol because it helps prevent "bad" cholesterol from building up in the arteries and protects against heart disease.
Triglycerides are another type of fat in the blood that can increase the risk of heart disease.
Ezetimibe/atorvastatin is used in patients who cannot control their cholesterol levels by diet alone. While you are taking this medicine, you should also follow a low-cholesterol diet.
Ezetimibe/atorvastatin is used, along with a low-cholesterol diet, if you have:
Ezetimibe/atorvastatin does not help you lose weight.
Warnings and precautions
Consult your doctor or pharmacist before you start taking ezetimibe/atorvastatin
Contact your doctor as soon as possible if you experience unexplained muscle pain, tenderness or weakness while taking ezetimibe/atorvastatin.This is because, on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage. Atorvastatin can cause muscle problems and muscle problems have also been reported with ezetimibe.
Also, tell your doctor or pharmacist if you experience persistent muscle weakness. You may need to have tests and additional medicines to diagnose and treat this condition.
Consult your doctor or pharmacist before you start taking ezetimibe/atorvastatin:
If you are in any of the above situations (or are unsure), consult your doctor before taking ezetimibe/atorvastatin, as your doctor will need to perform a blood test before starting your treatment with ezetimibe/atorvastatin, and possibly during treatment, to predict the risk you have of experiencing muscle side effects. The risk of muscle side effects (e.g. rhabdomyolysis) increases when certain medicines are taken at the same time (see section 2 "Other medicines and Ezetimibe/Atorvastatin Olpha").
While you are taking this medicine, your doctor will check if you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high levels of sugar and fat in the blood, are overweight and have high blood pressure.
Tell your doctor about all your medical conditions, including allergies.
The combined use of ezetimibe/atorvastatin and fibrates (certain medicines to lower cholesterol) should be avoided, as the combined use of ezetimibe/atorvastatin and fibrates has not been studied.
Children
Ezetimibe/atorvastatin is not recommended for children and adolescents.
Other medicines and Ezetimibe/Atorvastatin Olpha
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
There are some medicines that can affect the way ezetimibe/atorvastatin works or that ezetimibe/atorvastatin can affect. This type of interaction could reduce the effectiveness of one or both medicines or increase the risk or severity of side effects, including a serious condition called "rhabdomyolysis", which is described in section 4:
some medicines used to treat hepatitis C, e.g. telaprevir, boceprevir and the combination of elbasvir/grazoprevir, ledipasvir/sofosbuvir,
** If you have to take fusidic acid by mouth to treat a bacterial infection, you will have to stop using this medicine temporarily. Your doctor will tell you when you can restart the treatment with ezetimibe/atorvastatin. The use of ezetimibe/atorvastatin with fusidic acid can rarely cause muscle weakness, tenderness or pain (rhabdomyolysis). For more information about rhabdomyolysis, see section 4.
Taking Ezetimibe/Atorvastatin Olpha with food and drink
See section 3 for instructions on how to take ezetimibe/atorvastatin. Please note the following:
Grapefruit juice
Do not drink more than 1 or 2 small glasses of grapefruit juice per day, as large quantities of grapefruit juice can affect the way ezetimibe/atorvastatin works.
Alcohol
Avoid excessive alcohol consumption while taking this medicine. For more details, see section 2 "Warnings and precautions".
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Do not take ezetimibe/atorvastatin if you can become pregnant, unless you use reliable contraception. If you become pregnant while taking ezetimibe/atorvastatin, stop taking it immediately and tell your doctor.
Do not take ezetimibe/atorvastatin if you are breast-feeding.
The safety of ezetimibe/atorvastatin during pregnancy and breast-feeding has not yet been established.
Ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Ezetimibe/atorvastatin is unlikely to affect your ability to drive or use machines. However, it should be taken into account that some people experience dizziness after taking ezetimibe/atorvastatin.
Ezetimibe/Atorvastatin Olpha contains lactose
The tablets of Ezetimibe/Atorvastatin contain a sugar called lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Ezetimibe/Atorvastatin Olpha contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Take this medicine exactly as your doctor has told you. Your doctor will decide the appropriate dose of ezetimibe/atorvastatin for you, depending on your current treatment and your personal risk situation. If you are unsure, consult your doctor or pharmacist.
How much to take
The recommended dose is one ezetimibe/atorvastatin tablet once a day by mouth.
Method of administration
Take Ezetimibe/Atorvastatin Olpha at any time of day. You can take it with or without food.
If your doctor has prescribed ezetimibe/atorvastatin with colestyramine or any other bile acid sequestrant (medicines that lower cholesterol levels), you should take ezetimibe/atorvastatin at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you take more Ezetimibe/Atorvastatin Olpha than you should
Consult your doctor or pharmacist.
If you forget to take Ezetimibe/Atorvastatin Olpha
Do not take a double dose to make up for forgotten doses. The next day, take your normal dose of ezetimibe/atorvastatin at the usual time.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
If you experience any of the following serious adverse effects or symptoms, stop taking your tablets and inform your doctor immediately, or go to the emergency department of the nearest hospital.
Consult your doctor as soon as possible if you experience problems associated with the unexpected or unusual appearance of bleeding or bruising, as this fact may be indicative of liver disease.
The following frequent adverse effects have been reported (may affect up to 1 in 10 patients):
The following infrequent adverse effects have been reported (may affect up to 1 in 100 patients):
Additionally, the following adverse effects have been reported in people taking ezetimibe/atorvastatin, ezetimibe, or atorvastatin alone:
Consult your doctor if you experience weakness in the arms or legs that worsens after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or difficulty breathing.
Possible Adverse Effects Reported with Some Statins
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging or on the container after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Ezetimibe/Atorvastatin Olpha
The active ingredients are ezetimibe and atorvastatin. Each film-coated tablet contains 10 mg of ezetimibe and 10 mg, 20 mg, 40 mg, or 80 mg of atorvastatin (as atorvastatin calcium trihydrate).
The other ingredients are: calcium carbonate; anhydrous colloidal silica; sodium croscarmellose; hydroxypropylcellulose; lactose monohydrate; povidone, magnesium stearate; microcrystalline cellulose; polysorbate 80; sodium lauryl sulfate (E487).
The tablet coating contains: hypromellose, lactose monohydrate, titanium dioxide (E171), macrogol, talc.
Appearance of the Product and Package Contents
Film-coated tablets, biconvex, capsule-shaped, white to off-white.
Ezetimibe/Atorvastatin Olpha 10 mg/10 mg tablets EFG: with "1T" engraved on one side.
Ezetimibe/Atorvastatin Olpha 10 mg/20 mg tablets EFG: with "2T" engraved on one side.
Ezetimibe/Atorvastatin Olpha 10 mg/40 mg tablets EFG: with "4T" engraved on one side.
Ezetimibe/Atorvastatin Olpha 10 mg/80 mg tablets EFG: with "8T" engraved on one side.
Package sizes:
Packages of 10, 30, 90, and 100 film-coated tablets in aluminum/aluminum blisters.
Only some package sizes may be marketed.
Marketing Authorization Holder
Olpha AS,
Rupnicu iela 5,
Olaine, Olaines novads, LV-2114,
Latvia
Manufacturer
Delorbis Pharmaceuticals LTD,
17 Athinon street,
Ergates Industrial Area,
2643 Ergates Lefkosia,
Cyprus
This medicine is authorized in the Member States of the European Economic Area under the following names:
Slovakia: | Ezetimibe/Atorvastatin Olpha 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg film-coated tablets |
Spain: | Ezetimiba/Atorvastatina Olpha 10 mg/10 mg film-coated tablets EFG Ezetimiba/Atorvastatina Olpha 10 mg/20 mg film-coated tablets EFG Ezetimiba/Atorvastatina Olpha 10 mg/40 mg film-coated tablets EFG Ezetimiba/Atorvastatina Olpha 10 mg/80 mg film-coated tablets EFG |
Estonia: | Ezetimibe/Atorvastatin Olpha |
France: | Ezetimibe/Atorvastatine Olpha 10 mg/10 mg film-coated tablet Ezetimibe/Atorvastatine Olpha 10 mg/20 mg film-coated tablet Ezetimibe/Atorvastatine Olpha 10 mg/40 mg film-coated tablet Ezetimibe/Atorvastatine Olpha 10 mg/80 mg film-coated tablet |
Latvia: | Ezetimibe/Atorvastatin Olpha 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg film-coated tablets |
Lithuania: | Ezetimibe/Atorvastatin Olpha 10 mg/10 mg film-coated tablets Ezetimibe/Atorvastatin Olpha 10 mg/20 mg film-coated tablets Ezetimibe/Atorvastatin Olpha 10 mg/40 mg film-coated tablets Ezetimibe/Atorvastatin Olpha 10 mg/80 mg film-coated tablets |
Netherlands: | Ezetimibe/Atorvastatine Olpha 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg film-coated tablets |
Date of the last revision of this leaflet: November 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es